Clinical Trials Logo

ECMO clinical trials

View clinical trials related to ECMO.

Filter by:
  • None
  • Page 1

NCT ID: NCT06274411 Recruiting - ECMO Clinical Trials

Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention

ESCORT
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The goal of this multicenter, randomized trial is to compare standby cannulated ECMO versus prophylactic ECMO in patients undergoing high-risk percutaneous coronary intervention (PCI). The main question it aims to answer is : • If standby cannulated ECMO as compared with prophylactic ECMO will improve the outcomes in patients undergoing high-risk PCI

NCT ID: NCT06210542 Not yet recruiting - Clinical trials for Carbapenem-Resistant Enterobacteriaceae Infection

Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model

Start date: January 2024
Phase:
Study type: Observational

The goal of this study is to evaluate the efficacy and safety of ceftazidime-avibactam(CAZ-AVI) in the treatment of critically ill patients with carbapenem-resistant organisms(CRO) infections (including dialysis patients and extracorporeal membrane oxygenation(ECMO) patients).

NCT ID: NCT04990752 Recruiting - Clinical trials for Inflammatory Response

Effects of Ulinastatin on Inflammatory Response During ECMO Support

Uli-ECMO
Start date: July 26, 2021
Phase:
Study type: Observational [Patient Registry]

This study is a multicenter, prospective, observational cohort study. The subjects were patients who received ECMO support. According to whether ulinastatin is used in the treatment regimen (determined by the competent doctor according to the patient's condition), the patients were divided into the ulinastatin and control groups. In the ulinastatin group, ulinastatin was used for inflammation management and organ protection early before ECMO was started. Baseline data and inflammatory markers (CRP, IL-6, IL-10, TNF-α), capillary leakage markers, routine test results, duration of ECMO use/length of hospital stay/length of ICU stay were recorded at 1, 3, and 5 days after the start of ECMO support, and patients were followed up on the 28th and 90th days.

NCT ID: NCT04496362 Recruiting - Respiratory Failure Clinical Trials

Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study

Start date: October 10, 2018
Phase: Phase 4
Study type: Interventional

This single-center, open-label study will evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure.

NCT ID: NCT04478136 Withdrawn - Bleeding Clinical Trials

Can Blood Panels Provide Early Warning of Bleeding in Patients on ECMO?

Start date: December 1, 2021
Phase:
Study type: Observational

This is a prospective, observational study of 60 adult patients anticoagulated with bivalirudin for extracorporeal membrane oxygenation (ECMO). The study aims to identify the most precise early warning blood test or panel of blood tests to predict bleeding in patients on bivalirudin/ECMO. The project will involve comparing currently used blood tests with an extended panel of coagulation and metabolic blood tests with the aim of early warning of impending bleeding to allow intervention in the form of adjusted bivalirudin dose, modification of other risk factors, or transfusion with hemostatic products targeted to documented coagulation test abnormalities.

NCT ID: NCT04340414 Recruiting - COVID-19 Clinical Trials

Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP

Start date: February 20, 2020
Phase: N/A
Study type: Interventional

assess the safety and effectiveness of using low-flow extracorporeal membrane oxygenation(CO2 removal) driving by CVVH machine in the severe NCP patients

NCT ID: NCT03981393 Completed - Clinical trials for Acute Respiratory Failure

Cardinality Matching Study of Early v.s. Delayed VV ECMO in Severe Respiratory Failure

Start date: December 1, 2011
Phase:
Study type: Observational

Clinical reasoning and recent data suggest that early use of venovenous extracorporeal membrane oxygenation in refractory respiratory failure may confer a survival advantage. This retrospective matched study will assess whether patients who received VV ECMO at less severe hypoxaemia had differing outcomes to those who received ECMO with very severe hypoxaemia.